Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InNexus Biotechnology, a drug development company, has announced the results of an extensive mouse tumor study demonstrating superiority of the company's DXL625 compared to Rituxan in the xenograft model.
Subscribe to our email newsletter
The company has also launched a large scale study of DXL625 with primates, designed to evaluate toxicity and pharmokinetics, enabling the company to move the product to the FDA toward human testing.
Thomas Kindt, InNexus’s chief scientific officer, said: “A study performed by an independent group investigating the survival of mice intravenously injected with B-lymphoma cells and treated subsequently with DXL625 showed a significant improvement in outcome compared to animals treated with equivalent doses of Rituxan, a commercially available anti-CD20 antibody.
“Animals treated with either drug had a superior outcome when compared to those receiving inactive control (vehicle), however DXL625 had a substantial advantage over the competing antibody. We are confident that these results will translate to therapeutic advantage when DXL625 is used in human subjects.”